Emergent Nanotherapeutics in Diabetic Complications

Table of Contents

Part 1 Nanotherapeutics in Diabetic Comorbidities
1. Available nano-formulations in diabetes associated comorbidities and their mode of action for translational applications
2. Stimuli-responsive nanoplatforms for targeted drug release in diabetic complications: Clinical potential, scalability, and economic feasibility
3. Multifunctional nano-formulations: Integrating diagnosis, therapy, and real-time glucose monitoring for diabetic patients with current clinical status

Part 2 Nanotherapeutics for Microvascular Complications related to Diabetes
4. Nano-formulations for early-stage diabetic retinopathy: A visionary approach
5. Nano-formulations based renal protection: Combating diabetic nephropathy
6. Nano-formulations for diabetic neurpathy: Restoring nerve function
7. Engineering nanoparticles for improved bloodbrain barrier penetration in diabetic cognitive decline

Part 3 Nanotherapeutics for Macrovascular and Metabolic Complications related to Diabetes
8. Nano-formulation strategies for cardiovascular disease prevention in diabetes
9. Nanomedicine for hypertension in diabetes: Next-generation therapeutics for vascular protection
10. Nanotherapeutics for obesity-linked diabetes: A dual-action, effective approach
11. Nanotherapeutics for Dyslipidemia, NAFLD, and NASH: A multifaceted approach to metabolic liver disorders in diabetes

Part 4 Nanotherapeutics for Wound Healing and Tissue Regeneration in Diabetes
12. Nanotherapeutics for diabetic foot ulcers: Smart, clinically relevant wound healing and infection control for cost-effective care
13. Nano-formulation strategies for regenerative medicine in diabetes: Toward scalable and economical tissue restoration platforms

Part 5 Emerging Trends and Future Perspectives
14. Converging nanotechnology and CRISPR-Cas system revolutionize gene editing and diagnostics in diabetes
15. 3D and 4D printing of nanostructures: Clinically relevant and scalable technologies for revolutionizing diabetic wound healing
16. AI-driven design of nanotherapeutics for the treatment and management of personalized diabetes: Enhancing scalability, cost-effectiveness, and real-time glucose monitoring

Authors

Awanish Kumar Associate Professor and Head, Department of Biotechnology, National Institute of Technology Raipur, India. Dr. Awanish Kumar is an Associate Professor of the Department of Biotechnology at the National Institute of Technology, Raipur, Chhattisgarh, India. He has more than 13 years of research experience. He received his PhD in molecular parasitology from the CSIR-Central Drug Research Institute, Lucknow, India, and Jawaharlal Nehru University, Delhi, India, and completed his postdoctoral studies at McGill University, Montreal, Canada. His research interests are infection biology, drug targeting, and drug discovery. Gunjan Adwani Department of Biotechnology, National Institute of Technology, Raipur, India. Gunjan Adwani is a Ph.D. researcher in the Department of Biotechnology at the National Institute of Technology, Raipur, India. Her research focuses on nanomedicine, advanced drug delivery systems, and diabetes therapeutics, with a primary focus on optimizing insulin delivery strategies. She holds a Bachelor of Science and a Master of Science in Biotechnology from Pt. Ravishankar Shukla University, Raipur. Her current work involves the development of innovative nanocarrier platforms for targeted antidiabetic drug delivery and the formulation of therapeutic interventions to mitigate diabetic comorbidities.